ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 0521 • ACR Convergence 2024

    Transcriptome Analysis of Drug Response in a Large Cohort of Immune-Mediated Inflammatory Disease Patients Supports Advanced Combination Therapy in Rheumatoid Arthritis

    Ernest Choy1, Maria López Lasanta2, Paloma Vela-Casasempere3, Antonio Fernandez Nebro4, Santos Castañeda5, Carlos Marras6, Jaime Calvo-Alén7, Jesus Tornero8, Juan Cañete9, Eugeni Domènech10, Javier Gisbert11, José Manuel Carrascosa12, Eduardo Fonseca13, Luis Bujanda14, Valle García15, Britta Siegmund16, Giampiero Girolomoni17, Holger Heyn18, Pere Santamaria19, Richard M Myers20, yolanda Guillen21, Sergio H Martínez-Mateu22, Sara Marsal23 and Antonio Julia24, and IMID Consortium, 1Cardiff University School of Medicine, Cardiff, United Kingdom, 2Hospital Universitari Vall d´Hebron, Rheumatology, Barcelona, Spain, 3Hospital General Universitario Alicante, Alicante, Spain, 4Hospital Regional Universitario Carlos Haya , Rheumatology, Málaga, Spain, 5Hospital Universitario de la Princesa, Madrid, Spain, 6Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Murcia, Spain, 7Department of Rheumatology, Hospital Araba, Vitoria, Pais Vasco, Spain, 8Hospital Universitario de Guadalajara, Guadalajara, Spain, 9Hospital Clinic an IDIBAPS, Barcelona, Spain, 10Hospital Universitari Germans Trias i Pujol, Barcelona, Spain, 11Hospital Universitario de la Princesa and IIS-IP, Madrid, Spain, 12Hospital Universitari Germans Trias i Pujol, Badalona, Spain, 13Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain, 14Hospital Universitario de Donostia, San Sebastián, Spain, 15Hospital Universitario Reina Sofía, Córdoba, Spain, 16Charité – Universitätsmedizin Berlin, Berlin, Germany, 17University of Verona, Verona, Italy, 18Centre for Genomic Regulation (CNAG-CRG), National Centre for Genomic Analysis, Barcelona, Spain, 19Institut D'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain, 20HudsonAlpha Institute for Biotechnology, Huntsville, AL, 21Imidomics, Inc, Barcelona, Spain, 22IMIDOMICs, Barcelona, Spain, 23Vall Hebron Hospital Research Institute, Barcelona, Spain, 24Vall d'Hebron Hospital Research Institute, Barcelona, Spain

    Background/Purpose: Targeted therapies have failed to provide sustained disease remission in most patients suffering from immune-mediated inflammatory diseases (IMIDs). Combining existing drugs could overcome this…
  • Abstract Number: 0525 • ACR Convergence 2024

    Assess the Effect of Increasing the Dose of Folic Acid Supplementation in Patients of Rheumatoid Arthritis with Methotrexate Intolerance – A Randomised Controlled Trial

    Varun Dhir1, Harshith Sai Koneti2, Aman Sharma3, sanjay jain4 and shankar naidu5, 1PGIMER, CHD, INDIA, CHANDIGARH, India, 2PGIMER, Chandigarh, Sangareddy, Telangana, India, 3PGIMER, Chandigarh, India, Chandigarh, Chandigarh, India, 4PGIMER, Chandigarh, Chandigarh, India, 5PGIMER, Chandigarh, India, Chandigarh, India

    Background/Purpose: : Methotrexate (MTX) Intolerance continues to occur in 20-40% patients despite low-dose folic acid (5-10mg per week) supplementation. Would a higher dose of folic…
  • Abstract Number: 0514 • ACR Convergence 2024

    Efficacy, Safety and Mechanism of Butyrate in the Treatment of Rheumatoid Arthritis (RA)

    Jing He1, Naidi Wang2, Yuhui Li3, Ruoyi Wang2, Xiao Tan2, Runzhi Zhufeng2, Yipeng Han2, Hao Li2, Yuebo Jin2 and Zhanguo Li4, 1Rheumatology, Beijing, China, 2Department of Rheumatology and Immunology, Peking University People’s Hospital, Beijing, China, 3Peking University, BeiJing, China, 4People’s Hospital Peking University Health Sciences Centre, Beijing, China

    Background/Purpose: This study aims to investigate the safety and efficacy of butyrate capsules in treating patients with rheumatoid arthritis (RA) and elucidate the underlying mechanisms.Methods:…
  • Abstract Number: 0447 • ACR Convergence 2024

    Pregnancy Outcomes in Women Exposed to Guselkumab: Review of Cases Reported to the Manufacturer’s Global Safety Database

    Connie Lin1, Anja Geldhof2, Mauricio Ballina3, Hetal Patel4 and Hewei Li5, 1Janssen R&D US, Horsham, PA, 2Director Postmarketing Commitments, Leiden, Netherlands, 3Actelion Research & Development, Basel, Switzerland, Gewerbestrasse, Basel-Landschaft, Switzerland, 4Pharmaceutical Companies of Johnson & Johnson, Naperville, IL, 5Janssen Pharmaceutical, Hopewell Township, NJ

    Background/Purpose: Data pertaining to the use of biologics in immunologic diseases are limited on their use during pregnancy. Guselkumab (GUS) is a human IgG1λ mAb…
  • Abstract Number: 0509 • ACR Convergence 2024

    Trends in Initiation of Disease-Modifying Antirheumatic Drugs for Rheumatoid Arthritis Among Commercially-Insured US Adults, 2001-2021

    Lydia Lee1, Jeffrey Sparks2, Priyanka Yalamanchili1, Daniel B. Horton3, Zeba Khan4, Joseph Barone4 and Chintan Dave5, 1Rutgers University, New Brunswick, NJ, 2Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA, Boston, MA, 3Center for Pharmacoepidemiology and Treatment Science, Institute for Health, Health Care Policy, and Aging Research; Department of Biostatistics and Epidemiology, Rutgers School of Public Health; Department of Pediatrics, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, 4Rutgers University, New Brunswick, 5Center for Pharmacoepidemiology and Treatment Science, Institute for Health, Health Care Policy, and Aging Research; Center for Health Outcomes, Policy & Economics, Rutgers Ernest Mario School of Pharmacy and Rutgers School of Public Health, New Brunswick, NJ

    Background/Purpose: Despite the increasing availability of newer RA therapies, there is a paucity of data comprehensively evaluating long-term trends for individual DMARDs in the US.…
  • Abstract Number: 0490 • ACR Convergence 2024

    Improvements in Peri-fracture Care in Rheumatoid Arthritis (RA) Have Offset Increased Mortality

    Owen Taylor-Williams1, Johannes Nossent2 and Charles Inderjeeth3, 1University of Western Australia, Perth, Western Australia, Australia, 2University of Western Australia, Sir Charles Gairdner Hospital, Perth, Western Australia, Australia, 3SCGH and OPH Group & University of Western Australia, Perth, Western Australia, Australia

    Background/Purpose: Hip or pelvis fractures (HOP) are common osteoporotic fractures (OP) with significant risks of medical complications, placement into care, reduced quality of life and…
  • Abstract Number: 0519 • ACR Convergence 2024

    Comparable Malignancy Risk of Janus Kinase Inhibitors with Conventional Synthetic and Biologic DMARDs in Asian Patients with Rheumatoid Arthritis: A Comprehensive Analysis from Two Medical Centers

    Ming‑Han Chen1, Mao-Yuan Chen2, Shih-Hsin Chang3 and DER-YUAN CHEN4, 1Division of Allergy, Immunology & Rheumatology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, Taipei, Taiwan, 2Division of Allergy, Immunology & Rheumatology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan (Republic of China), 3Rheumatology and Immunology Center, China Medical University Hospital, Taichung, Taiwan (Republic of China), 4heumatology and Immunology Center, China Medical University Hospital, Taichung, Taiwan (Republic of China)

    Background/Purpose: JAK inhibitors (JAKi) and biologic disease-modifying antirheumatic drugs (bDMARDs) have proven efficacy in the treatment of rheumatoid arthritis (RA). However, their potential for increasing…
  • Abstract Number: 0303 • ACR Convergence 2024

    Phase 2b, Long-term Extension, Dose-ranging Study of Oral JNJ-77242113 for the Treatment of Moderate-to-Severe Plaque Psoriasis: FRONTIER-2

    Laura K. Ferris1, Jerry Bagel2, Yu-Huei Huang3, Andrew E. Pink4, Stephen K. Tyring5, Georgios Kokolakis6, Amy M. DeLozier7, Daniel Kakaley8, Shu Li9, Yaung-Kaung Shen10, Takayuki Ota7 and Robert Bissonnette11, 1University of Pittsburgh, Pittsburgh, PA, 2Psoriasis Treatment Center of Central NJ, East Windsor, NJ, 3Chang Gung Memorial Hospital and Chang Gung University, Linkou, Taoyuan City, Taiwan (Republic of China), 4NHS Foundation Trust Great Maze Pond, London, United Kingdom, 5Center for Clinical Studies, Webster, TX, 6Psoriasis Research and Treatment Center, Department of Dermatology, Venereology and Allergology, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, 7Janssen Research & Development, LLC, San Diego, CA, 8Janssen Scientific Affairs, LLC, Horsham, PA, 9Janssen Research & Development, LLC, Spring House, PA/San Diego, CA, 10Janssen Research & Development, LLC, Spring House, PA, 11Innovaderm Research, Montreal, QC, Canada

    Background/Purpose: JNJ-77242113, a targeted oral peptide, inhibits IL-23 signaling by binding the IL-23 receptor. At all doses, JNJ-77242113 showed superior efficacy at Week 16 versus…
  • Abstract Number: 0524 • ACR Convergence 2024

    Evaluating Dose Reduction of Biologic Treatments in Rheumatoid Arthritis: Predicting Flares Using Clinical and Molecular Biomarkers

    Laura Galindo Domínguez1, Belen Acasuso2, Vanesa Balboa-Barreiro3, Juan Fernández-Tajes2, Juan Cañete4, Benjamin Fernández-Gutiérrez5, Isidoro González-Álvaro6, José L Pablos7, Carmen Bejerano-Herreria8, Maite Silva-Díaz9, Franciso javier De-Toro-Santos2, Natividad Oreiro10 and francisco J Blanco11, 1Instituto de Investigacion Biomedica de A Coruña (INIBIC), A Coruña, Spain, 2Unidad de Investigacion Clinica. Grupo de Investigación de Reumatología (GIR). Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas., Investigation, A Coruña, Spain, A Coruña, Spain, 3Unidad de Epidemiología Clínica y Bioeostadística. Instituto de Investigación Biomédica de A Coruña (INIBIC). Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC)., A Coruña, Spain, 4Hospital Clinic an IDIBAPS, Barcelona, Spain, 53Rheumatology Department, and Health Research Institute (IdISSC), Hospital Clínico San Carlos, Calle del Profesor Martín Lagos, s/n, 28040, Madrid, Spain., Rheumatology, Madrir, Spain, Madrid, Madrid, Spain, 6University Hospital La Princesa, Madrid, Madrid, Spain, 7Health ministry, Madrid, Madrid, Spain, 8Hospital Universitario Marqués de Valdecilla, Santander, Spain, 9Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain, 10CHUAC, La Coruna, Galicia, Spain, 11INIBIC-University of A Coruña, A Coruña, Spain

    Background/Purpose: Reducing the dosage of biologic drugs in patients with rheumatoid arthritis (RA) who have achieved remission is a viable and necessary strategy. To identify…
  • Abstract Number: 0327 • ACR Convergence 2024

    Clinical and Immunological Risk Factors Associated with Fybromialgia in Patients with Idiopathic Inflammatory Myopathies

    Samuel Govea-Peláez1, Beatriz Alcalá-Carmona2, Jennifer Balderas Miranda3, Yatzil Reyna-Juárez2, María José Ostos-prado2, Nancy R Mejía-Domínguez2, Guillermo Juarez-Vega4, Jiram Torres Ruiz5 and Diana Gomez-martin6, 1INCMNSZ, Mexico City, Mexico, 2Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Distrito Federal, Mexico, 3Universidad Nacional Autónoma de México, Ciudad de México, Mexico, 4Red de Apoyo a la Investigación, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán and Universidad Nacional Autónoma de México, Mexico City, Distrito Federal, Mexico, 5INCMNSZ, Mexico, Federal District, Mexico, 6INCMNSZ, Mexico City, Federal District, Mexico

    Background/Purpose: Patients with idiopathic inflammatory myopathies (IIM) have reported chronic pain despite having normal serum muscular enzymes, physician global assessment (PhGA) and MMT8 scores, thus…
  • Abstract Number: 0433 • ACR Convergence 2024

    Male Perspective on Reproductive Health in Rheumatology Patients: A Cross-sectional Study

    Eleonora Giacobbe1, Maria Chiara Gerardi2, Clizia Gagliardi2, Sara Benedetti2, Giuseppina Di Raimondo2, Assunta Ascione3, Monica Barichello2, Nicola Ughi4, Antonella Adinolfi2, Laura Belloli2, Cinzia Casu2, Maria Di Cicco2, Davide antonio Filippini2, Matteo Longhi2, Bianca Lucia Palermo2, Martina Schettino2, Giulia Segatto2, Elisa Verduci2 and Oscar Massimiliano Epis2, 1Niguarda Hospital, Milan, Milan, Lombardia, Italy, 2Niguarda Hospital, Milan, Milan, Italy, 3Niguarda Hospital, Milan, Milan, 4Niguarda Hospital, Milan, Mila, Italy

    Background/Purpose: As reproductive health is gathering attention in rheumatology and all medical fields, the male perspective on the matter is often overlooked as not directly…
  • Abstract Number: 0499 • ACR Convergence 2024

    PD-1hiCXCR5-CD4+T Peripheral Helper Cells Enrich in Rheumatoid Arthritis and Predict Clinical Response to Anti-TNF Treatment

    Wanki Ho1, Huaqun Zhu1, Hua Ye1, Dongdong Fu2 and Xi Xu1, 1Peking University People's Hospital, Beijing, China, 2Xinxiang Central Hospital, Xinxiang, Henan, China (People's Republic)

    Background/Purpose: PD-1hiCXCR5-CD4+T peripheral helper cells (Tph) are newly identified pathogenic CD4+T helper cells and participate in rheumatoid arthritis (RA) pathogenesis. However, the clinical significance of…
  • Abstract Number: 0518 • ACR Convergence 2024

    Sustained Patient Meaningful Outcomes of Pain and Fatigue Relief and Improved Physical Functioning with Filgotinib in Rheumatoid Arthritis: A Post Hoc Analysis

    Rieke Alten1, Bruno Fautrel2, Philip G Conaghan3, Dick de Vries4, Margaux Faes5, Mercedes Piovesan6, Katrien Van Beneden7, Chris Watson8, Angelique E.A.M. Weel-Koenders9, Eugen Feist10 and Kurt de Vlam11, 1Department of Internal Medicine and Rheumatology, Schlosspark Klinik, University Medicine Berlin, Berlin, Germany, 2INSERM, UMRS 1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique, and Sorbonne University – Assistance Publique-Hôpitaux de Paris, Département de Rhumatologie, Hôpital Pitié-Salpêtrière, Paris, Ile-de-France, France, 3Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, 4Clinical Development, Galapagos BV, Leiden, Netherlands, 5Biostatistics, Galapagos NV, Mechelen, Belgium, 6Medical Affairs, Galapagos Biopharma Spain SLU, Madrid, Spain, 7Medical Affairs, Galapagos NV, Mechelen, Belgium, 8Medical Affairs, Galapagos Biotech Ltd, Cambridge, United Kingdom, 9Erasmus School of Health Policy and Management, Erasmus University Rotterdam, and Department of Rheumatology and Clinical Immunology, Maasstad Hospital, Rotterdam, Netherlands, 10Department of Rheumatology, Helios Clinic Vogelsang-Gommern, cooperation partner of the Otto von Guericke University Magdeburg, Gommern, Germany, 11Department of Rheumatology, UZ Leuven, and Department of Development and Regeneration, Skeletal Biology and Engineering Research Center, KU Leuven, Leuven, Belgium

    Background/Purpose: Quality of life for patients with RA can be severely impacted by pain, fatigue and impaired physical functioning.1 Filgotinib (FIL) has demonstrated early onset…
  • Abstract Number: 0526 • ACR Convergence 2024

    Comparing Immunogenicity and Safety Following Transition from Reference Rituximab to Biosimilar Rituximab (DRL_RI) in Patients with Rheumatoid Arthritis: A Randomized, Double-blind, Phase 3 Study

    Narendra Maharaj1, Dharma rao Uppada2, Naveen Reddy MAREDDY1, Pramod Reddy Pundra1, Anastas Batalov3, Delina Ivanova4, nedyalka staykova5, Asta Baranauskaite6 and Laila Hassan7, 1Clinical Development - Biologics, Dr. Reddy’s Laboratories Ltd., Bachupally, Hyderabad 500090, India, Hyderabad, India, 2Clinical Development - Biologics, Dr. Reddy’s Laboratories Ltd., Bachupally, Hyderabad 500090, India, Hyderabad, 3Medical University of Plovdiv, Medical Faculty, University Hospital "Kaspela", Clinic of Rheumatology, Plovdiv 4000, Bulgaria, Plovdiv, Bulgaria, 4Diagnostic and Consulting Center Aleksandrovska EOOD Sofia 1431, Bulgaria, Sofia, Bulgaria, 5Outpatient Clinic for Specialized Medical Help – Medical Center Kuchuk Paris OOD; Plovdiv 4004, Bulgaria, plovdiv, Bulgaria, 6Hospital of Lithuanian University of Health Sciences Kauno Klinikos, LT-50161, Lithuania, Kaunas, Lithuania, 711914 Astoria Blvd. Ste. 330, Houston TX 77089 United States, Houston, TX

    Background/Purpose: To assess immunogenicity and safety in patients with active rheumatoid arthritis (RA) transitioning from US-Rituximab (RP) or EU-Rituximab (RMP) to DRL_RI (proposed rituximab biosimilar),…
  • Abstract Number: 0434 • ACR Convergence 2024

    Pregnancy Outcomes of Biosimilars and Non-TNF Inhibitor Biologic Disease-Modifying Antirheumatic Drugs: A Scoping Review

    Vienna Cheng1, Neda Amiri2, Vicki Cheng1, Ursula Ellis3, Jacquelyn J. Cragg1, Mark Harrison1 and Mary A. De Vera1, 1University of British Columbia, Faculty of Pharmaceutical Sciences, Vancouver, BC, Canada, 2University of British Columbia, Faculty of Medicine, Vancouver, BC, Canada, 3University of British Columbia, Woodward Library, Vancouver, BC, Canada

    Background/Purpose: Biosimilar and biologic (b) DMARDs have revolutionized rheumatic disease management in the recent decades. As these drugs become introduced, it is important to understand…
  • « Previous Page
  • 1
  • …
  • 348
  • 349
  • 350
  • 351
  • 352
  • …
  • 2607
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology